# US 2025/0319136 A1 · Method for preparing oligodendrocytes and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0319136 A1
- Document ID: US20250319136A1
- Status: Published application
- Kind: A1
- Application number: 18/560,902
- Filed: 2022-07-05
- Published: 2025-10-16
- Earliest claimed: 2022-03-02
- Assignees: Shenzhen ExoNeuglia Biomedical Technology Co., Ltd.
- Applicants: Shenzhen ExoNeuglia Biomedical Technology Co., Ltd.
- Inventors: Ying GUO; Hong GAO
- Web page: https://patentgrep.com/patent/US20250319136A1

## CPC

- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/602: Sox-2
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/45: from artificially induced pluripotent stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of producing oligodendrocytes recapitulates the major steps of oligodendrocyte differentiation in a significantly shorter time than the 75-95 days required for the previous protocol. The cannabinoid receptor agonist, WIN55212-2, induces NSC differentiation and promotes OLIG2+OPC induction. WIN-derived OLIG2+ progenitor cells differentiate into PDGFR α+ OPCs, which are highly migratory, can further differentiate into mature OLs with strong myelination ability. When WIN-derived OPCs were transplanted to the lesion site, the motor ability of spinal cord injury (SCI) mice was significantly improved from the second week after transplantation. Immunostaining results showed that WIN-derived OPCs could differentiate into mature OLs and myelinate injured axons. The method and product have wide applications in the field of cellular therapy, especially for spinal cord injury with remarkable therapeutic effects.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

A method for producing oligodendrocytes, comprising:
(1) generating NSCs of PAX6+/NESTIN+/SOX2+: human induced pluripotent stem cells are cultured with neural induction medium from day 0 to day 7, and the medium is changed every day;
(2) from day 8, changing the medium to fresh N2 medium containing retinoic acid, Purmorphamine and CB receptor agonist every day;
(3) from day 12, manually isolating the cells and suspending them in N2B27 medium containing retinoic acid, Purmorphamine and CB receptor agonist, and changing the medium every other day;
(4) from day 20, further suspending spheroids in PDGF-AA medium;
(5) from day 30, seeding and culturing expanded spheroids on Matrigel-coated plates or Petri dishes with low growth factors in glial differentiation medium for 16-36 days;
wherein the concentration of the retinoic acid is 10-1000 nM, the concentration of the Purmorphamine is 0.1-10 μM, and the concentration of the CB receptor agonist is 1 μM in the medium of said (2) and (3), wherein the CB receptor agonist is WIN55212-2.

### Claim 21 (depends on 20)

The method according to claim 20, characterized in that said (1) is replaced with the NSC finished product of PAX6+/NESTIN+/SOX2+.

### Claim 22 (depends on 20)

The method according to claim 20, characterized in that the human induced pluripotent stem cells are cultured on Matrigel-coated six-well plates using mTeSR™M medium in a 37° C. incubator with 5% CO2.

### Claim 23 (depends on 21)

The method according to claim 21, characterized in that the human induced pluripotent stem cells are cultured on Matrigel-coated six-well plates using mTeSRTM medium in a 37° C. incubator with 5% CO2.

### Claim 24 (depends on 20)

The method according to claim 20, characterized in that the concentration of the retinoic acid is 100 nM, the concentration of the Purmorphamine is 1 μM, and the concentration of the CB receptor agonist is 1 μM.

### Claim 25 (depends on 20)

A medicament for treatment of a demyelinating disease or a myelin sheath injury disease, which is prepared by the method according to claim 20,
wherein the demyelinating disease is selected from the group consisting of spinal cord injury, stroke, multiple sclerosis, neuromyelitis optica, Guillain-Barre syndrome, diffuse disseminated cerebrospinal meningitis, acute disseminated encephalomyelitis, concentric sclerosis, diffuse sclerosis, leukodystrophy, leukoencephalopathy caused by ischemia-hypoxia disease, central pontine myelinolysis, acute inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyneuropathy, subacute combined degeneration caused by nutritional deficiency disease, subacute sclerosing panencephalitis or progressive multifocal leukoencephalopathy caused by viral infection, diabetic neuropathy, neuropathy of systemic lupus erythematosus, white matter ablation disease, adrenoleukodystrophy, and pelizois metzbach disease,
wherein the myelin sheath injury disease is selected from the group consisting of Down syndrome, Alzheimer's disease, and Parkinson's disease.

### Claim 26 (depends on 2)

A method for promoting neural stem cell differentiation into oligodendrocytes, comprising the method for producing oligodendrocytes according to claim 2l .
